FDA and EMA get comfortable in joint inspections; GSK, Pfizer provide discounted vax to GAVI;

> The FDA and the European Medicines Agency continue to cozy up, moving from confidence-building in their joint GMP inspections to reliance upon each other. Story

> GlaxoSmithKline ($GSK) and Pfizer ($PFE) say they will provide 180 million doses of discounted pneumococcal vaccine for use by the Global Alliance for Vaccines and Immunization. Story

> Covidien ($COV) says it plans to spin off its $2 billion pharmaceuticals business, creating a public company. Article

> DSM Sinochem Pharmaceuticals will build a production facility for semi-synthetic cephalosporins in Zibo, China. Story

> Pfizer ($PFE) has put three real estate lots--the last of its presence in Brooklyn--on the market. Item

> Contract service provider Advanced BioScience Labs has hired industry vet Claire Zhang to lead its downstream bioprocessing group. Item

> Lonza has expanded its early-phase, small-molecule manufacturing capacity in Nansha, China. Announcement

> Tom Flachmeyer has joined Prolong Pharmaceuticals to head the engineering and facilities planning function for it oxygen therapeutic product, Sanguinate. Story

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)